Clinical Trials Logo
  1. Home
  2. Advanced NSCLC
  3. NCT06356675

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC Clinical Trial

Official title:
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Clinical Trial Summary

Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy怂Targeted angiogenesis therapy has always been the focus of research on the treatment of NSCLC patients with progressive disease after immunotherapy. From the mechanism of action, angiogenesis and immunosuppression are interrelated processes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06356675
Study type Interventional
Source The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Contact linzhu zhai
Phone 02036492550
Email linzhuzhai@163.com
Status Not yet recruiting
Phase Phase 4
Start date July 1, 2024
Completion date July 1, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02133196 - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT00813332 - Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Phase 4
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT04982224 - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Phase 1/Phase 2
Recruiting NCT05609578 - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Phase 2
Not yet recruiting NCT04992858 - Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations Phase 2
Active, not recruiting NCT03127449 - AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations N/A
Completed NCT03074175 - Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancerļ¼šMulticenter Controlled Study.(RadmiR-01) N/A
Terminated NCT05106335 - A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC Phase 3
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Completed NCT05219162 - Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Phase 4
Not yet recruiting NCT05859217 - A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Phase 2
Recruiting NCT03062800 - Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) Phase 2
Completed NCT02055508 - POSITIVE - Study (Part III) Heidelberg N/A
Active, not recruiting NCT04043195 - Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Phase 1/Phase 2